Can treatment using radiolabelled somatostatin analogue increase the survival rate in patients with non-functioning neuroendocrine pancreatic tumours?

Sowa‐Staszczak, Anna; Pach, Dorota; Stefańska, Agnieszka; Tomaszuk, Monika; Lenda-Tracz, Wioletta; Mikołajczak, Renata; Pawlak, Dariusz; Chrzan, Robert; Gilis‐Januszewska, Aleksandra; Przybylik-Mazurek, Elwira; Hubalewska‐Dydejczyk, Alicja

doi:10.5603/nmr.2011.00019

Cited by 10 publications

(3 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A study by [1] showed conflicting results, founding difference in OS in the univariate analysis (small bowel NET had longer OS than pancreatic, lung and large intestine primaries) but not in the multivariate analysis. Reported median OS for non-functioning panNET was 25.7 months and for other NET was 46.7 months in the study of [72], but data were not statistically significant. A not significant trend towards a better PFS in panNETs was also reported by [59].…”

Section: "Negative Studies"mentioning

confidence: 68%

“…In 20 studies the role of primary in PRRT was analyzed in detail [1,4,5,12,15,21,24,27,32,35,42,46,59,60,68,70,72,78,79], but primary showed an impact on response to PRRT only in 8 [4,5,12,21,24,32,42,60]. No association was noted between positive and negative studies and patient populations, sample size, study design or radionuclide employed (177Lu or 90Y).…”

Section: Primarymentioning

confidence: 99%

See 1 more Smart Citation

PRRT: identikit of the perfect patient

Albertelli

Dotto

Dato

et al. 2020

Rev Endocr Metab Disord

View full text Add to dashboard Cite

Peptide receptor radionuclide therapy (PRRT) has been strengthened since the publication of NETTER-1. Nevertheless, the correct positioning in the therapeutic algorithm is debated, and no optimal sequence has yet been standardized. Possible criteria to predict the response to PRRT in neuroendocrine tumors (NET) have been proposed. The aim of this review is to define the perfect identity of the eligible patient who can mostly benefit from this therapy. Possible predictive criteria which have been analysed were: primary tumor site, grading, tumor burden, FDG PET and 68Ga-PET uptake. Primary tumor site and 68Ga-PET uptake do not play a pivotal role in predicting the response, while tumor burden, FDG PET uptake and grading seem to represent predictive/prognostic factors for response to PRRT. The heterogeneity in trial designs, patient populations, type of radionuclides, previous therapies and measurement of outcomes, inevitably limits the strength of our conclusions, therefore care must be taken in applying these results to clinical practice. In conclusion, the perfect patient, selected by 68Ga-PET uptake, will likely have a relatively limited liver tumor burden, a ki67 index <20% and will respond to PRRT irrespective to primary tumor. Nevertheless, we have mostly prognostic than predictive factors to predict the efficacy of PRRT in individual patients, while a promising tool could be the NETest. However, to date, the identikit of the perfect patient for PRRT is a puzzle without some pieces and still we cannot disregard a multidisciplinary discussion of the individual case to select the patients who will mostly benefit from PRRT.

show abstract

Section: "Negative Studies"mentioning

confidence: 68%

Section: Primarymentioning

confidence: 99%

PRRT: identikit of the perfect patient

Albertelli

Dotto

Dato

et al. 2020

Rev Endocr Metab Disord

View full text Add to dashboard Cite

show abstract

“…They concluded that PRRT is safe and effective in non-functioning pancreatic neuroendocrine tumors resulting in either disease regression or stabilization in most patients. There was no statistically significant survival difference in non-functional pancreatic neuroendocrine tumors when compared to other NETs post PRRT (13). …”

Section: Radiolabeled Peptidesmentioning

confidence: 96%

Targeted radionuclide therapies for pancreatic cancer

et al. 2015

View full text Add to dashboard Cite

Pancreatic malignancies, the 4th leading cause of cancer deaths, have an aggressive behavior with poor prognosis, resulting in a five-year survival rate of only 4%. It is typically a silent malignancy until patients develop metastatic disease. Targeted radionuclide therapies of cancer such as radiolabeled peptides which bind to the receptors overexpressed by cancer cells and radiolabeled antibodies to tumor-specific antigens provide a viable alternative to chemotherapy and external beam radiation of metastatic cancers. Multiple clinical trials of targeted radionuclide therapy of pancreatic cancer have been performed in the last decade and demonstrated safety and potential efficacy of radionuclide therapy for treatment of this formidable disease. While a lot progress has been made in treatment of pancreatic neuroendocrine tumors with radiolabeled with 90Y and 177Lu somatostatin peptide analogues, pancreatic adenocarcinomas remain a major challenge. Novel approaches such as peptides and antibodies radiolabeled with alpha emitters, pre-targeting, bispecific antibodies and biological therapy based on the radioactive tumorlytic bacteria might offer a potential breakthrough in treatment of pancreatic adenocarcinomas.

show abstract

Somatostatin (growth hormone release-inhibiting hormone) and analogues

2016

Meyler's Side Effects of Drugs

View full text Add to dashboard Cite

Can treatment using radiolabelled somatostatin analogue increase the survival rate in patients with non-functioning neuroendocrine pancreatic tumours?

Cited by 10 publications

References 14 publications

PRRT: identikit of the perfect patient

PRRT: identikit of the perfect patient

Targeted radionuclide therapies for pancreatic cancer

Somatostatin (growth hormone release-inhibiting hormone) and analogues

Contact Info

Product

Resources

About